Blood-based testing of mutations in patients with head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology

Fostira, Florentia; Oikonomopoulou, P.; Kladi, Athina; Edelstein, Daniel L.; Stieler, Kristin; Heim, Denise; Γκοτζαμανίδου, Μαρία; Anastasiou, Μaria; Kotsantis, Ioannis; Kavourakis, George; Gavrielatou, Niki; Kousidou, Evgenia; Vagia, Elena Vagia; Holtrup, Frank; Psyrri, Amanda

doi:10.1093/annonc/mdz252.050

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of positive cases in oral rinses was higher in tumors of the oral cavity or oropharynx than in tumors of the larynx. Fostira et al [ 66 ], using the SafeSEQ NGS technology, found a 51% and 93% tumor-plasma concordance in LA and R/M SCCHN, respectively.…”

Section: Current Evidencementioning

confidence: 99%

See 1 more Smart Citation

Liquid Biopsy in Head and Neck Cancer: Current Evidence and Future Perspective on Squamous Cell, Salivary Gland, Paranasal Sinus and Nasopharyngeal Cancers

Cabezas-Camarero

Pérez‐Segura

2022

Cancers

View full text Add to dashboard Cite

Head and neck cancer (HNC) is currently the sixth most common solid malignancy, accounting for a 50% five-year mortality rate. In the past decade, substantial improvements in understanding its molecular biology have allowed for a growing development of new biomarkers. Among these, the field of liquid biopsy has seen a sustained growth in HNC, demonstrating the feasibility to detect different liquid biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTC), extracellular vesicles and microRNAs. Liquid biopsy has been studied in HPV-negative squamous cell carcinoma of the head and neck (SCCHN) but also in other subentities such as HPV-related SCCHN, EBV-positive nasopharyngeal cancer and oncogene-driven salivary gland cancers. However, future studies should be internally and externally validated, and ideally, clinical trials should incorporate the use of liquid biomarkers as endpoints in order to prospectively demonstrate their role in HNC. A thorough review of the current evidence on liquid biopsy in HNC as well as its prospects will be conducted.

show abstract

Section: Current Evidencementioning

confidence: 99%

“…These and other smaller studies are summarized in Table 3 [ 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 ].…”

Section: Current Evidencementioning

confidence: 99%

Liquid Biopsy in Head and Neck Cancer: Current Evidence and Future Perspective on Squamous Cell, Salivary Gland, Paranasal Sinus and Nasopharyngeal Cancers

Cabezas-Camarero

Pérez‐Segura

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Thus, this method allows a correction of amplification and sequencing errors and can quantify rare mutations with a sensitivity of 0.05% of allele fraction. Safe-SeqS showed high performance in detecting mutations in cfDNA from patients with solid tumors, for molecular profiling as well as real-time monitoring of minimal residual disease [ 75 ]. A recent study on three independent cohort of nonmetastatic colorectal cancer, showed a median mutant allele frequency of 0.046% with a minimum of 0.01% [ 76 ].…”

Section: Detection Of Ctdna By Sequencing Technologiesmentioning

confidence: 99%

cfDNA Sequencing: Technological Approaches and Bioinformatic Issues

2021

View full text Add to dashboard Cite

In the era of precision medicine, it is crucial to identify molecular alterations that will guide the therapeutic management of patients. In this context, circulating tumoral DNA (ctDNA) released by the tumor in body fluids, like blood, and carrying its molecular characteristics is becoming a powerful biomarker for non-invasive detection and monitoring of cancer. Major recent technological advances, especially in terms of sequencing, have made possible its analysis, the challenge still being its reliable early detection. Different parameters, from the pre-analytical phase to the choice of sequencing technology and bioinformatic tools can influence the sensitivity of ctDNA detection.

show abstract